Research Advances Understanding of Gene Mutations in Bone Marrow Disorders and Blood Cancers

A Kyoto University research team has identified that germline mutations in the SLF2 and SMC5 genes cause inherited bone marrow failure syndrome and predispose patients to myelodysplastic syndromes. These mutations, previously linked to Atelis syndrome, trigger p53 activation and accelerate hematopoietic stem cell aging. Using CRISPR-Cas9 to correct SLF2 variants in patient-derived induced pluripotent stem cells successfully reversed these cellular abnormalities, offering new diagnostic and therapeutic pathways.

SLF2 gene mutations

• ▪Disruption of the SLF2 gene induces activation of the cancer-fighting p53 protein and leads to premature aging of hematopoietic stem cells.
• ▪Germline mutations in the SLF2 gene are a cause of inherited bone marrow failure syndrome.

SMC5 gene mutations

• ▪Disruption of the SLF2 gene induces activation of the cancer-fighting p53 protein and leads to premature aging of hematopoietic stem cells.
• ▪Germline mutations in the SLF2 gene are a cause of inherited bone marrow failure syndrome.

Inherited bone marrow failure

• ▪Germline variants in the SLF2 and SMC5 genes were previously linked to Atelis syndrome, a neurodevelopmental disorder frequently accompanied by blood abnormalities.
• ▪Inherited bone marrow failure syndrome describes a group of disorders where inherited genetic abnormalities impair the bone marrow's ability to produce sufficient healthy blood cells.

Myelodysplastic syndrome predisposition

• ▪Myelodysplastic syndromes are a group of blood cancers where the bone marrow produces excess abnormal blood cells and insufficient healthy ones.
• ▪Germline mutations in the SLF2 and SMC5 genes predispose individuals to developing myelodysplastic syndromes.

iPSC gene correction modeling

• ▪Researchers at Kyoto University established induced pluripotent stem cell lines from a patient carrying pathogenic SLF2 variants to study bone marrow failure.
• ▪Correcting SLF2 gene variants in patient-derived induced pluripotent stem cells using CRISPR-Cas9 gene editing reversed cellular abnormalities in vitro and in vivo.

Non-driver mutations

• ▪In a cohort of Japanese patients, the ASXL1 non-driver mutation was identified as a risk factor for leukemic transformation in myeloproliferative neoplasms, with a hazard ratio of 4.68.
• ▪A study of Japanese patients suggests that non-driver mutations hold prognostic value in essential thrombocythemia and polycythemia vera.

3 sources